Senseonics Holdings (SENS) Announces Positive Coverage Decision for Eversense CGM from Highmark Inc.

Senseonics Holdings, Inc. (NYSE: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced Highmark Inc. will begin providing coverage for the Eversense CGM effective September 28, 2020. This coverage decision adds to the growing number of payers who are writing Eversense into their CGM coverage policies, as well as paying for the healthcare provider’s time for the in-office sensor placement.

Highmark is among the top 10 largest health insurers in the United States, providing plans to residents across Pennsylvania, West Virginia and Delaware as an independent licensee of the Blue Cross Blue Shield Association. The organization provides plans to over 5.6 million members and is the largest healthcare insurer in Pennsylvania and the fourth-largest overall Blue Cross Blue Shield affiliate.

“Creating access to our CGM technology for diabetes patients through broad-based reimbursement is a priority for ensuring the long-term success of Eversense and our next-generation systems,” said Tim Goodnow, PhD, President and CEO of Senseonics. “It is encouraging to see the growing number of healthcare plans that recognize the value of our differentiated long-term implantable system and the benefits it provides to patients. We are pleased with this recent success and with our progress increasing patient access to date.”

You May Also Be Interested In

• Cushman & Wakefield names two capital markets leaders in APAC
• US DoE to Jumpstart Nuclear Supply Chain and Accelerate Deployment of Westinghouse AP1000 reactors
• TWO Announces Adjournment of Special Meeting